CASIF CASI Pharmaceuticals (CASIF) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001962738
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter
CASI Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CASI Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
1 fund bought in last quarter
Revenue
-27.4% year over year
below 71% of Pharma & Biotech
Margin
-232.0% net margin
below 67% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-26) · 95.7 days to cover · settled 2026-09-30
below 76% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CASIF
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns CASIF: institutional holders (13F)
13F holdings, latest reported quarter
100 sh
$17
Congress trades in CASIF
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CASIF planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
0 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CASIF financials
Revenue growth
-27.4%
XBRL, annual
Net margin
-232.0%
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $20.7M | $28.5M | $33.9M | $43.1M |
| Gross profit | $10.1M | $11.1M | $20.1M | $27.3M |
| Operating income | -$45.0M | -$39.6M | -$25.1M | -$34.0M |
| Net income | -$48.1M | -$39.3M | -$27.0M | -$41.0M |
| EPS (diluted) | -2.59 | -2.56 | -2.02 | -3.01 |
| Operating cash flow | -$20.8M | -$29.2M | -$20.0M | -$21.1M |
| Cash | $5.6M | $13.5M | $17.1M | $47.1M |
| Long-term debt | n/a | n/a | $18.9M | n/a |
| Buybacks | n/a | n/a | $278.0K | $3.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
CASIF Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
